Targets › IRAK1
2 programs from 2 companies in 19 trials: 11 Phase 2, 7 Phase 1, 1 Phase 3; Oncology, Hematology, Immunology; next expected readout Dec 2026.
Serine/threonine-protein kinase that plays a critical role in initiating innate immune response against foreign pathogens. Involved in Toll-like receptor (TLR) and IL-1R signaling pathways. (UniProt, P51617)
Open in Phaseline: the race on IRAK1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Swedish Orphan Biovitrum | Pacritinib Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Activin receptor type-1 inhibitor | JAK2, FLT3, ACVR1, IRAK1 | Phase 3 | Primary Myelofibrosis; VEXAS; Myelofibrosis; Acute Myeloid Leukemia … | Dec 2026 |
| Theradex | Pacritinib Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Activin receptor type-1 inhibitor | JAK2, FLT3, ACVR1, IRAK1 | Phase 2 | Leukemia, Myelomonocytic, Chronic | Jul 2028 |
Primary Myelofibrosis (2) Myelofibrosis (2) VEXAS (1) Acute Myeloid Leukemia (1) T-Cell Neoplasm (1) Myelofibrosis,MF (1) Waldenström Macroglobulinemia (1) Accelerated Phase Myeloproliferative Neoplasm (1) Prostate Cancer (1) KSHV Inflammatory Cytokine Syndrome (KICS) (1) Breast Cancer (1) E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic Syndrome (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.